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Inherited coding variants at the CDKN2A locus
inﬂuence susceptibility to acute lymphoblastic
leukaemia in children
Heng Xu1,2,*, Hui Zhang1,3,*, Wenjian Yang1, Rachita Yadav4, Alanna C. Morrison5, Maoxiang Qian1,
Meenakshi Devidas6, Yu Liu7, Virginia Perez-Andreu1, Xujie Zhao1, Julie M. Gastier-Foster8, Philip J. Lupo9,
Geoff Neale10, Elizabeth Raetz11, Eric Larsen12, W. Paul Bowman13, William L. Carroll14, Naomi Winick15,
Richard Williams16, Torben Hansen17, Jens-Christian Holm18, Elaine Mardis19, Robert Fulton19,
Ching-Hon Pui20,21, Jinghui Zhang7, Charles G. Mullighan20,22, William E. Evans1,20, Stephen P. Hunger23,
Ramneek Gupta4, Kjeld Schmiegelow24, Mignon L. Loh25, Mary V. Relling1,20 & Jun J. Yang1,20
There is increasing evidence from genome-wide association studies for a strong inherited genetic
basis of susceptibility to acute lymphoblastic leukaemia (ALL) in children, yet the effects of
protein-coding variants on ALL risk have not been systematically evaluated. Here we show a
missense variant in CDKN2A associated with the development of ALL at genome-wide sig-
niﬁcance (rs3731249, P¼9.4 10 23, odds ratio¼ 2.23). Functional studies indicate that this
hypomorphic variant results in reduced tumour suppressor function of p16INK4A, increases the
susceptibility to leukaemic transformation of haematopoietic progenitor cells, and is preferentially
retained in ALL tumour cells. Resequencing the CDKN2A–CDKN2B locus in 2,407 childhood ALL
cases reveals 19 additional putative functional germline variants. These results provide direct
functional evidence for the inﬂuence of inherited genetic variation on ALL risk, highlighting the
important and complex roles of CDKN2A–CDKN2B tumour suppressors in leukaemogenesis.
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T
he risk of developing acute lymphoblastic leukaemia (ALL)
is highest between 2 and 5 years after birth1,2, with
initiating sentinel somatic genomic lesions (for example,
chromosomal translocations) detectable at the time of birth in
many cases3,4. This early disease onset suggests a strong inherited
genetic basis for ALL susceptibility, and recent genome-wide
association studies (GWAS) have discovered at least six
risk loci: ARID5B, IKZF1, CEBPE, PIP4K2A-BMI1, GATA3 and
CDKN2A–CDKN2B5–10. These ALL risk genes are directly
involved in haematopoietic stem cell function, lymphocyte
differentiation and development, and cell cycle regulation11–15,
several of which are also commonly targeted by somatic genomic
lesions. In particular, the CDKN2A–CDKN2B locus is one of the
most frequently deleted genomic regions in childhood ALL with
focal copy number loss in both B- and T-cell ALL14,16.
The vast majority of variants examined in previous ALL
GWAS are intronic or intergenic. Although it is now evident that
non-coding variants related to disease traits are signiﬁcantly over-
represented in regulatory DNA and often function as modulators
of local or distal gene transcription17,18, questions also arise
whether coding variants within ALL susceptibility genes might
confer even greater effects on disease development. Moreover, a
large number of low-frequency and rare-coding germline variants
have been discovered by exome-sequencing efforts19, but their
contributions to ALL pathogenesis have yet to be examined
systematically.
In the present study, we perform an exome-focused GWAS to
systematically examine the impact of germline-coding variants on
the development of ALL in children of European descent,
experimentally explore the functional consequences of the
genome-wide signiﬁcant variant in the CDKN2A gene, and
comprehensively characterize coding variation at this locus by
targeted resequencing.
Results
Exome-focused GWAS of ALL susceptibility. In the discovery
GWAS, we genotyped 1,773 children with B-ALL and 10,448
non-ALL controls of European descent20,21 for 247,505 variants
using the Illumina Inﬁnium HumanExome array. Three loci with
genome-wide signiﬁcant association signals were observed:
ARID5B (10q21.2), IKZF1 (7q12.2) and CDKN2A (9p21.3)
(Fig. 1). Non-coding variants rs10821936 in ARID5B and
rs4132601 in IKZF1 showed the strongest association
(P¼ 9.9 10 46 and 4.3 10 37, the logistic regression test,
respectively; Fig. 1 and Supplementary Table 1), conﬁrming
previous GWAS ﬁndings from our group and others5,6. No
coding variants in ARID5B and IKZF1 were signiﬁcantly
associated with ALL susceptibility. The third genome-wide
signiﬁcant hit was a missense SNP at the CDKN2A locus
(rs3731249, P¼ 9.4 10 23, the logistic regression test, Fig. 1,
Table 1). The T allele at rs3731249 was over-represented in ALL
compared with controls (6.8% versus 3.0%, Table 1), with every
copy of the allele conferring 2.23-fold increase in disease risk
(95% conﬁdence interval 1.90–2.61). The C-to-T nucleotide
substitution at rs3731249 (c.C442T) resulted in an alanine-to-
threonine change in amino-acid sequence (p.A148T) for tumour
suppressor p16INK4A. This variant also locates in the 30
untranslated region (30-UTR) of the p14ARF transcript, an
alternative open reading frame at this locus encoding a
different tumour suppressor. Interestingly, previous GWAS had
identiﬁed an intronic variant in CDKN2A (rs3731217) to be
strongly associated with susceptibility to ALL in populations of
European descent9. Genotype correlation between the coding
variant rs3731249 and the intronic rs3731217 is exceedingly low
(r2o0.01 in Europeans, Supplementary Fig. 1), and multivariate
analyses including both SNPs indicated their independent
contribution to ALL risk (Supplementary Table 2). In the
replication cohort of 409 childhood ALL cases and 1,599 non-
ALL controls of European descent in Denmark, the association
signal at rs3731249 was validated (P¼ 5.2 10 4, odds
ratio¼ 1.73 (1.27–2.36), the logistic regression test, Table 1)
and this variant also remained signiﬁcant after adjusting for
rs3731217.
Functional characterization of the rs3731249 variant. To
experimentally evaluate the effects of rs3731249 on ALL leukae-
mogenesis, we directly compared the effect of wildtype versus
variant allele p16INK4A (p.148A versus p.148 T) on BCR–ABL1-
mediated leukaemic transformation in vitro. We chose mouse
haematopoietic progenitor Ba/f3 cell line because it is inherently
p16Ink4a-defective due to methylation at the Ink4a-Arf locus22,
and ectopic expression of BCR-ABL1 in Ba/f3 cells efﬁciently
induces exogenous cytokine (interleukin 3 (IL3))-independent
proliferation. Over-expression of wild-type p16INK4A(p.148A)
signiﬁcantly inhibited leukaemic transformation by BCR–ABL1
(Fig. 2a, Supplementary Fig. 2), consistent with its role as a critical
tumour suppressor in ALL. In contrast, Ba/f3 cells overexpressing
variant p16INK4A(p.148 T) were signiﬁcantly more susceptible to
BCR–ABL1 transformation measured by IL3-independent
growth, suggesting that the p.148 T variant is likely
hypomorphic with reduced tumour suppressor function. In
Ba/f3 cells transfected with both variant and wild-type
p16INK4A, the relative ratio of the p.148 T (variant) to p.148A
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Figure 1 | GWAS results of ALL susceptibility in European Americans. Association between genotype and ALL was evaluated for 35,802 SNPs in 1,773
ALL cases and 10,448 non-ALL controls. P-values (the logistic regression test,  log10 P, y axis) were plotted against respective chromosomal position of
each SNP (x axis). Gene, symbols were indicated for 3 loci achieving genome-wide signiﬁcance threshold (Po5 108, dashed blue line): ARID5B
(10q21.2), IKZF1 (7p12.2) and CDKN2A (9p21.3). Blue dots indicated SNPs within 2Mbp of the top ALL susceptibility variants at the ARID5B (rs10821936)
and IKZF1(rs4132601) loci, the red dots indicated SNPs in the 2M-bp region around the novel ALL risk variant rs3731249 in CDKN2A.
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(wildtype) transcript increased substantially upon BCR–ABL1-
mediated transformation (Supplementary Fig. 3), consistent with
the increased leukaemia risk conferred by the variant allele at
rs3731249. To further examine the potential susceptibility to ALL
conferred by the rs3731249 in patients, we compared the
genotype distribution in RNA and DNA from primary
leukaemic blasts and matched germline samples from children
with ALL (Fig. 2b). Of 15 cases with the heterozygous germline
genotype at this SNP, six exhibited somatic deletion of one copy
of CDKN2A, all of which retained the risk allele in tumour cells.
Even in cases not affected by somatic copy number loss at this
locus, the variant p16INK4A(c.442 T) was preferentially transcribed
relative to wildtype (c.442C), with allele-biased expression
ranging from 61 to 100%, Fig. 2b). Altogether, these results
pointed to the possibility that cells carrying the hypomorphic risk
allele at rs3731249 might have been enriched during
leukaemogenesis.
Targeted resequencing of CDKN2A and CDKN2B in childhood
ALL. To comprehensively identify putative functional ALL
susceptibility variants at this locus, we resequenced the coding
region of the CDKN2A and CDKN2B genes in germline DNA from
2,407 childhood ALL cases (1,450 of which were also included in the
discovery GWAS). In addition to rs3731249, we observed another
13 germline exonic variants in tumour suppressors p16INK4A and
p14ARF encoded by the CDKN2A gene, 12 of which result in
amino-acid sequence changes (Fig. 3, Supplementary Table 3).
These missense variants were all singletons, except for the p.D125H
variant in p16INK4A and the p.A121T variant in p14ARF observed in
two and ﬁve cases, respectively. Five variants were predicted to be
damaging based on combined annotation dependent depletion23
(CADD score413, Supplementary Table 3), and we did not observe
germline insertions or deletions in CDKN2A in our ALL cohort.
Comparing with 4,300 European American individuals from the
NHLBI GO Exome Sequencing Project (ESP), there was a trend for
a higher burden of rare missense variants in relative to controls the
CDKN2A gene (p16INK4A and p14ARF) in children with ALL
(0.71% versus 0.23%, P¼ 0.0045, Fisher’s exact test, Fig. 3). In
addition, we identiﬁed six germline-coding variants in the adjacent
CDKN2B gene in this cohort of children with ALL, although there
was no signiﬁcant over-representation compared with European
controls in the ESP cohort (0.83% versus 0.79%, Fig. 3).
Discussion
Encoding three tumour suppressor proteins (p16INK4A, p14ARF
and p15INK4B), the CDKN2A–CDKN2B locus at 9p21 is
promiscuously associated with tumorigenesis and commonly
Table 1 | Genome-wide signiﬁcant association and replication of novel coding B-ALL susceptibility variant at CDKN2A locus.
SNP ID Chr Position* Gene Allelesw Geno-
type
GWAS series Replication series
Case
(N¼ 1,773)
Control
(N¼ 10,441)
P-value ORz
(95% CI)
Case
(N¼410)
Control
(N¼ 1,599)
Pvalue ORz
(95% CI)
rs3731249 9 21970916 CDKN2A C/T TT 8 (0.45%) 7 (0.07%) 9.4 10 23 2.23
(1.90–2.61)
7 (1.71%) 2 (0.13%) 5.22 10 4 1.73
(1.27–2.36)
CT 224
(12.63%)
619 (5.93%) 45 (10.98%) 130 (8.13%)
CC 1,541
(86.92%)
9,815 (94%) 357 (87.07%) 1,467 (91.74%)
Chr, chromosome; CI, conﬁdence interval; GWAS, genome-wide association studies; OR, odds ratio; SNP, singleinucleotide polymorphism.
*Chromosomal locations are based on hg19
wBold denotes the allele that had a signiﬁcantly higher frequency in children with B-ALL than in the non-ALL controls (that is, risk allele for B-ALL)
zOR represents the increase in the risk of developing ALL for each copy of the risk allele compared with subjects who do not carry the risk allele; P- values and ORs were estimated by the logistic
regression test.
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Figure 2 | Functional characterization of ALL risk variant at rs3731249.
(a) Mouse haematopoietic progenitor cell Ba/f3 overexpressing wildtype,
variant p16INK4A, or transfected with control vector was transduced with
leukaemia oncogenic BCR–ABL1 fusion gene. Cell proliferation in the
absence of cytokine IL3 was measured daily as an indicator of leukaemic
transformation. Ectopic expression of p16INK4A (p.148 T, green) signiﬁcantly
potentiated leukaemic transformation by BCR–ABL1, compared with cells
expressing wild-type p16INK4A (p.148A, blue), consistent with the
association of this allele with susceptibility to ALL. Data represent the mean
of three replicates±s.e.m. (b) Allele-speciﬁc expression of p16INK4A in ALL
blasts was determined by comparing the number of sequence reads for
transcripts containing C or T alleles at rs3731249 (p16INK4Ap.148A versus
p16INK4Ap.148T), in 15 childhood ALL cases with heterozygous genotype in
the germline DNA at this SNP. Each dot represents an ALL case (red
indicates cases with somatic deletion (loss of heterozygosity) and blue
indicates cases without copy number change in tumour) and the line of
identity indicates equal expression of both alleles. P-value was estimated by
paired t-test based on the number of sequence reads for each allele.
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targeted by somatic mutation, deletion and/or hypermethylation
in various cancers. p16INK4A and p15INK4B are highly homo-
logous inhibitors of cyclin-dependent kinase and function mainly
as master regulators of cell cycle entry via the Rb-E2F signalling
axis24. Although also encoded by the CDKN2A gene, p14ARF
utilizes a completely different reading frame with distinct tumour
suppression functions by inhibiting MDM2 and activating p5325.
Suppressed during normal haematopoiesis, p16INK4A and p14ARF
expression is activated on oncogenic stimuli (for example,
constitutive expression of BCR-ABL1 fusion) to trigger cell cycle
exit (senescence) or apoptosis as a means of eliminating
oncogene-stressed cells26. In fact, the CDKN2A–CDKN2B locus
is either bi- or monoallelicly deleted in 64% of BCR–ABL1-
positive ALL cases and in 32–72% of T- or B-ALL cases without
the BCR-ABL1 translocation, suggesting positive selection for
cells with defective p16INK4A, p14ARF and p15INK4B (or some
combinations thereof) during leukaemogenesis.
The previously reported ALL susceptibility variant rs3731217 is
located in a non-coding region downstream of exon 1b (speciﬁc
for p14ARF), but distal to exon 1a (speciﬁc for p16INK4A) of the
CDKN2A gene. The germline genotype at this SNP was not
associated with overall CDKN2A expression in lymphoblastoid
cell lines9 but transcript-speciﬁc analyses may be needed to
deﬁnitively determine the effects of this variant on p14ARF versus
p16INK4A expression. In contrast, the genome-wide signiﬁcant
variant rs3731249 in our current GWAS localizes to exon 2 of
CDKN2A. While this exon is shared by both p16INK4A and
p14ARF, the C-to-T nucleotide transition causes a missense
change for the p16INK4A open reading frame but is in the UTR of
the p14ARF, therefore, likely to have a more direct effect on the
former. This hypothesis is supported by the fact that
haematopoietic progenitor cells (Ba/f3) expressing variant
p16INK4A were substantially more susceptible to BCR–ABL1-
mediated leukaemic transformation compared with cells with the
wild-type protein (Fig. 2a), pointing to rs3731249 as a possible
functional variant directly contributing to the association with
ALL risk. The structural basis of the hypomorphic effects of the
p.A148T variant is unclear, since this residue is not directly
involved in binding to CDK4 or CDK627. However, there was
evidence that the variant p16INK4A (p.148 T) is preferentially
retained in the nucleus compared with the wild-type p16INK4A
(p.148A), compromising its ability to inhibit CDKs in the
cytoplasm28,29. The relative contribution of p16INK4A versus
p14ARF to ALL pathogenesis is not unequivocal because somatic
deletions at this locus almost always lead to the loss of both genes.
Although the rs3731249 variant also results in sequence changes
of the 30-UTR of the p14ARF transcript, bioinformatic prediction
did not identify any potential effects on mRNA stability or
microRNA binding and no difference was observed in reporter
gene transcription under the inﬂuence of 30-UTR containing
either the wildtype or variant allele at rs3731249 (Supplementary
Fig. 4), suggesting minimal effects of this variant on p14ARF
transcription. Finally, rs3731249 is also observed in non-
European populations, for example, there was a trend for a
higher frequency of the risk allele in African American children
with ALL than that in individuals from this racial background in
the NHLBI ESP cohort (0.58% in 260 ALL cases versus 0.38% in
2,203 controls), although a much larger sample size is needed to
rigorously examine the statistical signiﬁcance of such differences.
It should be noted that we and others previously showed that the
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Figure 3 | Targeted resequencing of CDKN2A–CDKN2B locus identiﬁed additional germline coding variants in children with ALL. CDKN2A and CDKN2B
genes were sequenced using Illumina HiSeq platform following capture-based enrichment of this genomic region in 2,407 ALL cases of European descent.
Variants in non-ALL controls were based on publicly available data from the individuals of European descent within the NHLBI Exome Sequencing Project
(N¼4,300). Exonic variants are classiﬁed as silent or missense (grey or purple solid circles) and are mapped to three distinct open reading frames at this
locus: p16INK4A, p14ARF and p15INK4B, for ALL cases (red vertical lines) and non-ALL controls (blue vertical lines), and functional domains are indicated by
colour based on Pfam annotation. Each circle represents a unique individual carrying the indicated variant (heterozygous or homozygous), except for
variants recurring in more than 10 individuals for which the number in the circle indicates the exact frequency of the observed variant.
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non-coding ALL risk variants (rs17756311 and rs3731217) at this
locus had much stronger effects in European Americans than in
other race/ethnic groups7,30, suggesting potential racial
differences in genetic susceptibility to ALL.
We subsequently identiﬁed additional coding variants in
p16INK4A, p14ARF and p15INK4B by resequencing, most of which
were low frequency or rare. While there was a modest over-
representation of potentially damaging coding variants in ALL
cases compared with controls (Fig. 3), our data do not suggest
that rare variants contribute substantially to the associations with
ALL susceptibility observed at this locus. It should also be noted
that the vast majority of coding variants within the CDKN2A gene
affects only one of the two tumour suppressors (either p16INK4A
or p14ARF). Interestingly, rs199888003 is the only variant that is
located in the coding region of both p16INK4A and p14ARF,
resulting in an alanine-to-threonine change in p14ARF (p.A121T)
with synonymous effect on p16INK4A. This is also the most
frequent germline missense variant in p14ARF in our cohort and
was over-represented in ALL compared with non-ALL controls
(0.21% versus 0.046%, respectively, Fig. 3). This substitution of
threonine in p14ARF adds a possible glycosylation and phosphor-
ylation site and also introduces a phosphoprotein-binding FHA
domain implicated in DNA damage response and cell cycling31.
Future studies are warranted to determine the exact consequences
of this variant on p14ARF functions. To systemically evaluate the
contribution of low frequency and rare-coding variants to ALL
risk, we also performed genome-wide gene-level burden test but
did not observe any genome-wide signiﬁcant associations
(Supplementary Table 4). Of the six known ALL risk loci, we
noted two coding variants in CEBPE (rs141903485 and
rs146580935, Supplementary Table 5) nominally associated with
ALL susceptibility.
In conclusion, we comprehensively evaluated exonic genetic
variations for association with ALL susceptibility and identiﬁed
novel coding risk variants at the CDKN2A–CDKN2B locus that
may directly affect tumour suppressor functions and potentiate
leukaemic transformation. These results provided functional
evidence for the inﬂuence of inherited genetic variants on ALL
leukaemogenesis, further indicating that a continuum of genetic
variations in both host and tumour genomes contribute to
malignant transformation and cancer risk.
Methods
Subjects and samples. The discovery GWAS consisted of 1,773 childhood B-ALL
cases and 10,448 non-ALL controls of European descent (490% European genetic
ancestry as estimated using STRUCTURE32,33). ALL cases were from the
Children’s Oncology Group (COG) AALL0232 study (N¼ 1,277)8, the COG P9906
protocol (N¼ 115)34 and St Jude Total Therapy XIIIB and XV protocols
(N¼ 381)5. Unrelated individuals of European descent from the Atherosclerosis
Risk in Communities (ARIC) study20,21 were used as non-ALL controls because the
prevalence of adult survivors of childhood ALL is less than 1 in 10,000 in the US.
The replication series included 409 children with ALL from NOPHO ALL92,
ALL2000 and ALL2008 protocols35 and 1,599 unrelated non-ALL controls from
Danish Childhood Obesity Biobank study (clinicaltrials.gov: NCT00928473) in
Holbæk and at random schools in Zealand, Denmark. ALL cases were selected only
on the basis of sample availability, and we did not observe any statistically
signiﬁcant differences in demographic or clinical features of children included
versus not included in this genetic study. We elected to focus on individuals of
European descent to minimize population stratiﬁcation36.
Germline DNA for cases was extracted from peripheral blood or bone marrow
samples obtained during clinical remission (o5% ALL blasts by morphology). This
study was approved by the Institutional Review Board at St Jude Children’s
Research Hospital and COG member institutions and the Ethics Committee at the
Danish Data Protection Agency, Region Zealand and the University Hospital
Rigshospitalet, Denmark. Informed consent was obtained from parents, guardians,
or patients, as appropriate.
Genotyping and quality control. SNP genotyping was performed in germline
DNA using the Illumina Inﬁnium HumanExome Array v1.0 in the discovery
GWAS, and using Illumina HumanCoreExome chip for the replication series.
Genotype calls (coded as 0, 1, and 2 for AA, AB and BB genotypes) were determined
using the Illumina GenomeStudio Software. For the ALL cases, samples for which
genotype was ascertained ato98% of SNPs on the array were deemed to have failed
and were excluded from the analyses. Quality control procedures were performed
for both samples and SNPs on the basis of call rate, minor allele frequency (MAF),
and Hardy Weinberg equilibrium (Supplementary Fig. 5). Detailed quality control
for the non-ALL controls from the ARIC study was performed at the University of
Texas Health Science Center following established protocols21.
We performed principal component analysis of cases and controls in the
discovery GWAS to characterize population substructure (Supplementary Fig. 6).
Genome-wide analyses. In the discovery GWAS, the association of each SNP
individually with ALL susceptibility was tested by comparing the genotype
frequency between ALL cases and non-ALL controls in logistic regression models,
after adjusting for top 10 principal components to control for population
stratiﬁcation. A quantile–quantile (Q–Q) plot was constructed and there was only
minimal inﬂation at the upper tail of the distribution (l¼ 1.08, Supplementary
Fig. 7). In the replication studies, we evaluated the novel genome-wide signiﬁcant
variant rs3731249, using the same logistic regression models. Multivariate
logistic regression model including both rs3731217 and rs3731249 were tested to
determine independent association signals at the CDKN2A locus in both discovery
and replication series.
We also performed gene-level analyses to evaluate the aggregated effects of
low-frequency variants on ALL susceptibility, using the SKAT test37. Missense, stop
codon-altering and splice-site variants with MAFo5% were included. In total,
12,687 genes with at least two variants were tested.
R (version 3.0) statistical software was used for all analyses unless indicated
otherwise.
CDKN2A–CDKN2B resequencing and rare variant analyses. Germline DNA
from 2,407 children with ALL was used to create individual Illumina dual-indexed
libraries. These libraries were pooled in sets of 96 and hybridized with a custom
version of the Roche NimbleGen SeqCap EZ custom probes to capture the
CDKN2A–CDKN2B region on 9p21. Quantitative PCR was used to determine the
appropriate capture product titre necessary to efﬁciently populate an Illumina
HiSeq 2000 ﬂowcell for paired-end 2 101 bp sequencing. Each sequence pool of
96 samples was demultiplexed, with coverages of 420 depth across 490% of
the targeted regions for nearly all samples. Sequence reads in FASTQ format were
mapped and aligned using the Burrows–Wheeler Aligner, and genetic variants were
called using the GATK pipeline version 3.1 (ref. 38). We compared the proportion
of rare variant-carriers in ALL subjects (either homozygous or heterozygous)
versus that in individuals of European descent in the ESP cohort (non-ALL
controls), focusing on variants with MAFo1%. Statistical signiﬁcance of the
difference was estimated using Fisher’s exact test.
CDKN2A sequencing was also performed in matched germline and diagnostic
ALL tumour DNA by Complete Genomics for all cases with available materials,
and in tumour RNA by RNA-seq. Details regarding sequencing, data analysis and
coverage are available at ftp://caftpd.nci.nih.gov/pub/dcc_target/ALL/Phase_II/
sequence/WGS/CGI_TARGET_Pipeline_README.pdf, or as previously
described39 (European Genome Phenome archive: EGAS00001000654).
Leukaemic transformation assay in Ba/f3 cells. The full-length CDKN2A was
purchased from GE Healthcare. The p.A148T variant (rs3731249) was introduced
by site-directed mutagenesis (forward primer: 50-TGCCCGCATAGATGCCACGG
AAGGTCCCTCAGA-30 , reverse primer: 50-TCTGAGGGACCTTCCGTGGCAT
CTATGCGGGCA-30) and cloned into the cL20c-IRES–GFP lentiviral vector,
and lentiviral supernatants containing cL20c–p16INK4Ap.148A–IRES–GFP or
cL20c–p16INK4Ap.148 T–IRES–GFP were produced by transient transfection of
293 T cells (American Type Culture Collection) using calcium phosphate. The
MSCV (Babe MCS)–BCR–ABL1–Luc2 construct was a gift from Dr Charles Sherr
at St Jude Children’s Research Hospital22 and retroviral particles were produced
using 293 T cells. Ba/f3 cells (gift from Dr Omar Abdel-Wahab at the Memorial
Sloan Kettering Cancer Center) were maintained in medium supplemented with
10 ngml 1 recombinant mouse IL3. Ba/f3 cells were transduced with lentiviral
supernatants with wild-type or variant p16INK4A(Supplementary Fig. 8). GFP-
positive cells were sorted 48 h after transduction and maintained in IL3 medium for
another 24 h before transfected by BCR–ABL1 retroviral supernatants. Forty-eight
hours later, cells were washed three times and grown in the absence of cytokine.
Cell growth and viability were monitored daily by Trypan blue using
a TC10 automated cell counter (BIO-RAD). Each experiment was performed
three times.
For immunoblotting assays, Ba/f3 cells were washed and resuspended in lysis
buffer (10 PBS with 0.5M EDTA, 10% NP-40 and 50% glycerol) with protease
inhibitors and phosphatase inhibitors. Lysates were sonicated six times and
centrifuged at 13,000 g for 10min at 4 C. Supernatants were quantiﬁed for protein
concentration by BCA kit, electrophoresed, and transferred to nitrocellulose
membranes. Membranes were probed with 1: 1,000 anti-p16INK4A antibody
(Abcam, ab81278), with a-tubulin as a loading control (1: 1,000 anti-tubulin
antibody, Sigma-Aldrich, T5618).
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For quantitative reverse transcription-PCR (qRT–PCR), total RNA was
extracted using the RNeasy Micro kit (Qiagen) according to the manufacturer’s
protocol. Total RNA (500 ng) was reverse transcribed into cDNA using oligoT
primers and the SuperScript III reverse transcriptase kit (Invitrogen). Quantitative
real-time PCR was performed by using ABI Prism 7900HT detection system
(Applied Biosystems) with Faststart SYBR Green master mix (Roche). Relative
expression was calculated as a ratio of BCR-ABL1 to Hprt. Primer sequences of
BCR–ABL1 and Hprt were as follows: BCR-ABL1 (forward: 50-CTGGCCCAACG
ATGGCGA-30 ; reverse: 50-CACTCAGACCCTGAGGCTCAA-30); Hprt (forward:
50-GAGCAATGATCTTGATCTTC-30; reverse: 50-TTCCTTCTTGGGTATGG
AAT-30).
To co-express rs3731249 variant and wild-type p16INK4A, Ba/f3 cells were
transduced with equal molar cL20c–p16INK4Ap.148A–IRES–GFP and cL20c–
p16INK4Ap.148T–IRES–iYFP lentivirus and cells successfully transfected with both
were selected by ﬂow cytometry sorting for GFP/YFP double positivity. BCR-ABL1-
mediated transformation was performed as described above. Genomic DNA and RNA
samples were collected at day 0, 2, 4 and 5 after IL3 removal. p.148A and p.148T
transcript in RNA was quantiﬁed using allele-speciﬁc Taqman genotyping assay and
normalized to allele ratio in matched DNA samples at respective time points. Each
experiment was performed three times and each sample was assayed in triplicate.
Luciferase reporter assays. The p14INK4A–30-UTR vector (30-UTR for Human
NM_058195.2 was placed downstream of luciferase reporter gene on the pEZX-
MT01 backbone) was purchased from GeneCopoeia and the T variant at rs3731249
was introduced by site-directed mutagenesis (forward primer: 50-CCATGCCCGC
ATAGATGCCGTGGAAGGTCCCTCAGACATCC-30; reverse primer: 50-GGAT
GTCTGAGGGACCTTCCACGGCATCTATGCGGGCATGG-30). For reporter
gene assay, 2.5 104 293 T cells cultured in 96-well plate were transiently trans-
fected with 100 ng empty vector, variant, or wild-type p14INK4A 30UTR constructs
using Lipofectamine 2000 (Invitrogen). Fireﬂy luciferase activities were measured
24 h later using the Dual Luciferase Assay (Promega). The results were normalized
against Renilla luciferase. Each reporter construct transfection was replicated at
least three times, and each sample was assayed in triplicate.
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